These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20005029)

  • 1. Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors.
    Nelson RG; Tuttle KR
    Am J Kidney Dis; 2010 Mar; 55(3):426-30. PubMed ID: 20005029
    [No Abstract]   [Full Text] [Related]  

  • 2. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
    Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
    BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
    Hirst JA; Taylor KS; Stevens RJ; Blacklock CL; Roberts NW; Pugh CW; Farmer AJ
    Kidney Int; 2012 Apr; 81(7):674-83. PubMed ID: 22189841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of direct renin inhibition to chronic kidney disease.
    Mende CW
    Cardiovasc Drugs Ther; 2010 Apr; 24(2):139-49. PubMed ID: 20490905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
    Leon SJ; Tangri N
    Can J Cardiol; 2019 Sep; 35(9):1220-1227. PubMed ID: 31472818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.
    Siragy HM; Carey RM
    Am J Nephrol; 2010; 31(6):541-50. PubMed ID: 20484892
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.